medigraphic.com
ISSN 1405-1699 (Print)
Órgano Oficial del Colegio Mexicano de Alergia, Asma e Inmunología Pediátrica y de la Asociación Latinoamericana de Pediatría

2012, Number 2

<< Back Next >>

Alerg Asma Inmunol Pediatr 2012; 21 (2)

Differential diagnosis of peripheral eosinophilia and new options for its treatment

Bailón FNC, Huerta LJG, Gutiérrez HJA

Language: Spanish
References: 14
Page: 63-71
PDF size: 152.00 Kb.


ABSTRACT

The eosinophils are differentiated granulocytes that represent from 1 to 5% of the total leukocytes in peripheral blood, which actively participate in the pathogenesis of diverse inflammatory processes result of infections, of unspecific tissue damage, of immunological and tumor-like answer, and allergic diseases. Eosinophilia defined as an account of eosinophils of 0.5 x 103 in adults, and 0.75 x 103 in children; classically it has been related to allergic and infectious causes; nevertheless, it is necessary to establish a suitable diagnostic route that allows us to differentiate these from other causes of clinical relevance, such as the hypereosinophilic syndrome, myeloproliferative diseases, Churg Strauss syndrome, and others with multisystemic affection, with the purpose of to offer the suitable and opportune treatment to the patients with these affections. At present new therapeutic alternatives to the first line treatment with steroid, based on the use of inhibiting monoclonal antibodies of the interleukin-5 (IL-5), mepolizumab, are being developed.


REFERENCES

  1. Hoffman R. Hematology: Basic principles and practice. 5a Ed. 2008: 26.

  2. Adkinson NF. Middleton’s allergy: principles and practice. 7a Ed. 2009: 18: 205-308; 49: 859-875.

  3. Klion AD. Approach to the therapy of hypereosinophilic syndromes. Immunol Allergy Clin N Am 2007; 27: 551-560.

  4. Nutman TB et al. Evaluation and differential diagnosis of marked, persistent eosinophilia. Immunol Allergy Clin N Am 2007; 27: 529-549.

  5. Ogbogu PU, Bochner BS et al. Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy. J Allergy Clin Immunol 2009; 124: 1319-1325.

  6. Butterfield JH et al. Treatment of hypereosinophilic syndromes with prednisone, hydroxyurea, and interferon. Immunol Allergy Clin N Am 2007; 27: 493-518.

  7. Stein, ML, Villanueva JM et al. Anti–il-5 (mepolizumab) therapy reduces eosinophil activation ex vivo and increases il-5 and il-5 receptor levels. J Allergy Clin Immunol 2008; 121: 1473-1483.

  8. Simon D et al. Eosinophilic disorders. J Allergy Clin Immunol 2007; 119: 1291-1300.

  9. Akdis M, Burgler S et al. Interleukins, from 1 to 37, and interferon-g: receptors, functions, and roles in diseases. J Allergy Clin Immunol 2011; 127: 701-721.

  10. Jacobsen EA, Taranova AG et al. Eosinophils: Singularly destructive effector cells or purveyors of immunoregulation? J Allergy Clin Immunol 2007; 119: 1313-1320.

  11. Busse WW, Ring AJ. A review of treatment with mepolizumab, an anti–IL-5 in hypereosinophilic syndromes and asthma. J Allergy Clin Immunol 2010; 125: 803-813.

  12. Wechsler ME. Pulmonary eosinophilic syndromes. Immunol Allergy Clin N Am 2007; 27: 477-492.

  13. Méndez, Huerta y cols. Alergia: enfermedad multisistémica. Fundamentos básicos y clínicos. 1ª Ed. Edit Panamericana. 2008; 48: 110-111, 417.

  14. Smith DA, Minthorn EA, Beerahee M. Pharmacokinetics and pharmacodynamics of mepolizumab, an anti-interleukin-5 monoclonal antibody. Clin Pharmacokinet 2011; 50(4): 215-227.




2020     |     www.medigraphic.com